Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by Ciaoon Nov 07, 2022 11:29pm
132 Views
Post# 35080910

RE:RE:RE:RE:RE:RE:RE:Licensing agreement?

RE:RE:RE:RE:RE:RE:RE:Licensing agreement?The PGX demo plant should be at 10L. Scaling up 5 to 10 X takes it to 50 to 100 L which is adequate for commercial production. 

It's been said that scaling up was to allow Ceapro to go alone with their PGX YBG immune booster and in parallel the capacity could be used for any commercial PGX alginate or YBG substrates to be loaded with bioactives. So yes, scaling up takes them to commercial production if a licenced deal is reached, but the current demo plant does allow initial NCC to be produced with customer desired bioactives for product development. Risk averse Ceapro is scaling up to commercial production capacity for an immune booster based on a demo unit. Potential customers don't have much risk here at this stage.
<< Previous
Bullboard Posts
Next >>